Catalogo Ricerca

Catalogo Ricerca: [57090] Home page macrotipologia

Sfoglia

1 Contributo su Rivista 46709
- 1.1 Articolo in rivista 39249
- 1.1.1 Articolo in rivista - Review 1667
- 1.1.2. Articolo in Rivista - Letter, Note 854
- 1.1.3. Articolo in Rivista - Editorial, Comment, Reply 1142
- 1.1.4. Guidelines, Consensus 111
- 1.1.5. Erratum 192
- 1.2 Recensione in rivista 283
- 1.3 Scheda bibliografica 14
- 1.4 Nota a sentenza 0
- 1.5 Abstract in rivista 3185
- 1.6 Traduzione in rivista 12

2 Contributo in Volume 3181

3 Libro 780
- 3.1 Monografia o trattato scientifico 644
- 3.2 Concordanza 0
- 3.3 Indice 5
- 3.4 Bibliografia 12
- 3.5 Edizione critica 24
- 3.6 Pubblicazione di fonti inedite 5
- 3.7 Commento scientifico 13
- 3.8 Traduzione di libro 77

4 Contributo in Atti di Convegno (Proceeding) 5687
- 4.1 Contributo in Atti di convegno 2259
- 4.2 Abstract in Atti di convegno 3017
- 4.3 Poster 411

5 Altro 112
- 5.01 Preprint 12
- 5.02 Composizione 0
- 5.03 Disegno 0
- 5.04 Design 0
- 5.05 Performance 3
- 5.06 Esposizione 0
- 5.07 Mostra 1
- 5.08 Manufatto 1
- 5.09 Prototipo d'arte e relativi progetti 0
- 5.10 Cartografia 0
- 5.11 Banca dati 1
- 5.12 Software 12
- 5.13 Altro 82
- 5.14 Progetto architettonico 0
- 5.15 Articolo su portale o periodico 0

6 Brevetti 176
- 6.1 Brevetto 176

7 Curatele 198
- 7.1 Curatela 198

8 Tesi di dottorato 247
- 8.1 Tesi di dottorato 247

Prodotti recenti

End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)

AimsSerelaxin is recombinant human relaxin-2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy. In the RELAX-AHF trial, serelaxin demonstrated reductions in cardiac, renal and hepatic damage. In RELAX-AHF-2, organ damage-related biomarkers were assessed in a biomarker substudy.Methods and resultsPatients enrolled within 16 h of presentation for heart failure hospitalization were randomized to 48-h infusions of either serelaxin (30 mu g/kg/day) or placebo, a...

Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy

Introduction: Patients with biliary tract cancers (BTCs) often require antibiotic therapy before starting systemic treatment that includes an immune checkpoint inhibitor. This study aimed to evaluate the prognostic impact of antibiotic therapy administered in the 15 days prior to the start of chemoimmunotherapy in patients with BTC. Methods: The study population included patients with metastatic or locally advanced BTC from Western and Eastern populations treated with first-line chemoimmunoth...

Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study

Introduction: The potential for curative conversion with immunotherapy-based systemic treatment used with noncurative intent in patients with hepatocellular carcinoma (HCC) remains debated. This study aimed to provide a reliable epidemiological snapshot of response patterns to atezolizumab plus bevacizumab (AB) therapy, with a focus on curative conversion rates. Methods: Patients with HCC undergoing first-line noncurative AB or lenvatinib (LENV, used as reference) from 2019 to 2023 were inclu...

The Influence of Repeated Abutment Changes on Peri-Implant Tissue Stability and Keratinised Tissue on Peri-Implant Health: 12-Year Post-Loading Results From a Multicentre Randomised Controlled Trial

AimsTo evaluate the influence of at least three abutment disconnections in conventionally loaded implants against placement of a definitive abutment in immediately non-occlusal loaded implants on hard and soft tissue changes. A secondary aim was to evaluate whether the presence of less than 2 mm of keratinised mucosa is associated with increased peri-implant marginal bone loss and soft tissue recessions.MethodsSixty patients requiring one single crown or one fixed partial prosthesis supported...

Letter Re: Reflections on the MAGIC-D Prognostic Model in Advanced Biliary Tract Cancer

Scopri

Accesso al fulltext

no fulltext49430
open4210
reserved3319
partially open93
embargoed38